How a nineteenth-century drug wholesaler became the backbone of American healthcare distribution

How a nineteenth-century drug wholesaler became the backbone of American healthcare distribution
Image: Intellect (generated)

In short: Founded in 1828 as a small botanical drug importer, McKesson has evolved into the largest healthcare company in the United States. Today, it manages a massive infrastructure network, delivering one-third of all pharmaceutical products in North America while navigating complex legal battles and major corporate transformations over two centuries.

McKesson began in New York City as a modest enterprise under Charles M. Olcott. Through the mid-19th century, it expanded into a partnership known as McKesson & Robbins. The company survived a catastrophic 1938 accounting scandal, where executives fabricated a quarter of its $86,556,270 in assets to mask systematic theft. This watershed event forced a total overhaul of American auditing standards, yet the firm persisted, eventually shifting its focus from botanical imports to the high-tech logistics that define its modern operations.

The company's scale today is staggering. With $308.9 billion in 2024 revenue, it serves as a critical node in the US medical supply chain. During the COVID-19 pandemic, the federal government tapped McKesson as the centralized distributor for hundreds of millions of vaccine doses and ancillary supply kits. Beyond logistics, its software division supports vast swathes of the American medical system, including 50% of all health systems and 77% of hospitals with more than 200 beds. This reach is matched by its role in the retail pharmacy sector, where it owns the Health Mart network.

However, this growth has been accompanied by intense scrutiny. McKesson has faced numerous federal and state lawsuits alleging that its distribution practices fueled the American opioid epidemic. In 2008, it paid $13 million in fines for failing to report suspicious hydrocodone orders, followed by a $150 million civil penalty in 2017 regarding opioid distribution. By 2022, the company joined a $26 billion settlement alongside other major distributors to resolve thousands of state-level claims. Despite these legal headwinds, McKesson remains a dominant force, recently pivoting toward specialized medical services and planning to spin off its medical-surgical unit to further refine its corporate focus.

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

  • Summary by Intellect · source: McKesson

To cite this card, link to https://intellectplus.co.uk/app/wealth-mckesson.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…